REGN 8-K 2026-01-12

REGENERON PHARMACEUTICALS, INC. (REGN) 8-K dated 2026-01-12 — accession 0001104659-26-002691. This URL is the filing, not the REGN hub.

REGENERON PHARMACEUTICALS, INC. (REGN) is a biotechnology company listed on US. It is led by Leonard S. Schleifer M.D., Ph.D..

REGENERON PHARMACEUTICALS, INC. filed a 8-K on 2026-01-12. Accession 0001104659-26-002691.

Cached items: 2.02, 7.01, 9.01. EDGAR remains the official archive; Lician keeps this accession as its own indexable page so Google can recrawl the form, not a ticker dump.

Latest reported REGN revenue for 2026-06-30 was $4.29B. Net income was $1.30B. Revenue was up 19.0% from 2026-03-31 to 2026-06-30. REGN currently screens at market cap $59.10B and trailing P/E 13.9.

Not investment advice. The REGN SEC hub lists recent forms. The stock page is the research view.